To sustain momentum, Hims recently announced a deal with Novo Nordisk A/S (NYSE: NVO ) to distribute branded Wegovy at discounted rates. That partnership marks a notable departure from the firm's earlier reliance on generics and compounded imitators, indicating a move toward legitimizing its pharmaceutical offerings through strategic alliances.